Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
IDYA Catalyst Timeline
Dated clinical, regulatory and corporate events for IDEAYA Biosciences, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for IDEAYA Biosciences, Inc.
Upcoming catalysts 2
Event history 50
Past FDA Catalysts and PDUFA Decisions
How IDYA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-11-16 | IDE892 | Phase 1 data presentation | Phase 1 |
Drug Pipeline Intelligence
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| IDE892 Small MoleculesNCT07277413 | NSCLC Adenocarcinoma | Phase 1 | RECRUITING | 260 | Apr 30, 2028 | ||||||
| IDE-161 Small MoleculesNCT05787587 | Advanced or Metastatic Solid Tumors | Phase 1 | ACTIVE NOT_RECRUITING | 216 | May 1, 2027 | ||||||
| IDE849 Antibody-Drug Conjugates (ADCs)NCT07174583 | Small-cell Lung Cancer | Phase 1/2 | RECRUITING | 262 | Jul 1, 2029 | ||||||
| IDE034 Small MoleculesNCT07503808 | Esophageal Squamous Cell Carcinoma | Phase 1 | RECRUITING | 150 | Jul 30, 2027 | ||||||
| IDE397 Small MoleculesNCT04794699 | Solid Tumor | Phase 1 | ACTIVE NOT_RECRUITING | 169 | Feb 4, 2027 | ||||||
| IDE574 Small MoleculesNCT07540572 | Cancer | Phase 1 | RECRUITING | 155 | Jan 31, 2030 | ||||||
| Darovasertib Small MoleculesNCT05907954 | Uveal Melanoma | Phase 3 | ACTIVE NOT_RECRUITING | 1,130 | Apr 30, 2030 | ||||||
| Darovasertib Small MoleculesNCT05987332 | Metastatic Uveal Melanoma | Phase 2/3 | ACTIVE NOT_RECRUITING | 756 | Jan 15, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every IDYA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| IDE849 | relapsed small cell lung cancer and neuroendocrine carcinomas | Phase 1 | 2026-10-23 | median os 2L SCLC: 17.4 months; overall response rate 2L SCLC: 72.5%; median os 2L plus 3L SCLC: 14.7 months; overall response rate 2L plus 3L SCLC: 68.3%; overall response rate SCLC with brain metastases: 76.9%; overall response rate NEC: 52.6%; median pfs 2L SCLC: 6.9 months; median pfs 2L plus 3L SCLC: 6.8 months; median pfs NEC: 7.0 months; nine month os rate NEC: 82.4%Read More | IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroendocrine CarcinomasRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Hata Yujiro SDirector, Officer (President and CEO) | Option | 26,338 717,033 held | $4.31 | 10/06/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in IDYA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BAKER BROS. ADVISORS | 0.9 % | 192.49 M | 5.01 M |
Ownership Trends
IDYA Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How IDYA ranks across every disease it competes in
IDYA News
IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a Potential Best-in-Class DLL3 TOP1 ADC, in Neuroendocrine Carcinomas
IDEAYA Biosciences announced a successful Type C meeting with the FDA regarding IDE849, a DLL3-targeting ADC for neuroendocrine carcinomas. The company plans to initiate a single-arm extension cohort and a randomized Phase 3 trial to support potential accelerated and full approval. IDE849 has shown promising efficacy with a 52.6% overall response rate in previous trials.
Read more →IDEAYA Biosciences Announces Development Candidate Nomination of IDE101, a Potential First-In-Class Inhibitor Targeting CDKN2A-Deficiency in Solid Tumors
IDEAYA Biosciences has nominated IDE101 as a development candidate targeting CDKN2A-deficiency in solid tumors. The drug shows encouraging preclinical activity, particularly in pancreatic cancer. IND-enabling studies are currently underway, with plans to file for FDA approval in the first half of 2027. The company aims to combine IDE101 with other therapies to enhance efficacy.
Read more →IDEAYA Biosciences to Participate in Upcoming November 2026 Investor Relations Events
IDEAYA Biosciences will participate in key investor events on November 16-17, 2026, in London. The events will feature discussions on IDE892, a potential best-in-class PRMT5 inhibitor, and updates on RAS-driven cancer therapies. Registration is required for both in-person and virtual attendance.
Read more →IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update
IDEAYA Biosciences reported strong financial results for Q3 2026, including a successful NDA submission for darovasertib in metastatic uveal melanoma. The company presented promising data at ESMO 2026, highlighting the drug's potential as a foundational therapy. However, IDEAYA also announced the closure of the Phase 3 OptimUM-010 trial due to enrollment issues, resulting in cost reallocations.
Read more →IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences announced the grant of non-qualified stock options for 99,600 shares to four new employees as part of its 2023 Inducement Plan. The options, priced at $32.89 per share, will vest over four years, promoting long-term commitment. This action complies with Nasdaq Listing Rule 5635(c)(4).
Read more →IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroendocrine Carcinomas
IDEAYA Biosciences announced updated Phase 1 results for IDE849, showing promising anti-tumor activity in relapsed small cell lung cancer (SCLC) and neuroendocrine carcinomas (NECs). The study reported a median overall survival of 17.4 months in second-line SCLC and a 72.5% overall response rate. Plans for two Phase 3 trials are underway following successful FDA meetings.
Read more →IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Journey of Uveal Melanoma
IDEAYA Biosciences presented encouraging data on darovasertib at ESMO 2026, highlighting its effectiveness in treating metastatic and primary uveal melanoma. The trials OptimUM-01 and OptimUM-02 demonstrated significant clinical benefits, including improved progression-free survival and overall survival rates. Additionally, the OptimUM-09 trial showed promising tumor shrinkage and eye preservation rates, supporting darovasertib's potential as a foundational therapy.
Read more →IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development
IDEAYA Biosciences has promoted Dr. Michael White to President of Research and Development, effective September 28, 2026. Dr. White, previously Chief Scientific Officer, has been instrumental in advancing the company's oncology pipeline. His leadership is expected to enhance IDEAYA's efforts in developing targeted therapies for various cancers, aiming to address significant unmet medical needs.
Read more →IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma
IDEAYA Biosciences and Servier have announced the dosing of the first patient in the OptimUM-11 Phase 3 trial. This study evaluates the combination of darovasertib and crizotinib as an adjuvant therapy for patients with primary uveal melanoma at risk of metastasis. The trial aims to establish a new treatment option in a setting with significant unmet needs.
Read more →IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences
IDEAYA Biosciences has announced its upcoming Investor R&D Day in London on November 16, 2026, where it will discuss its development strategies for pancreatic cancer. The company will also participate in several investor conferences in September 2026, featuring key management discussions. A live audio webcast will be available for those unable to attend in person.
Read more →IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer
IDEAYA Biosciences announced a successful FDA Type C meeting regarding the Phase 3 registrational trial design for IDE849, a DLL3-targeting ADC in extensive stage small cell lung cancer (ES-SCLC). The company aims to begin the trial by the end of 2026, with a focus on overall response rate and median overall survival as primary endpoints. The study will enroll approximately 400 patients and evaluate various dose levels.
Read more →IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer
IDEAYA Biosciences has announced a clinical collaboration with Genentech to evaluate IDE892, a potential best-in-class PRMT5 inhibitor, in combination with Genentech's KRAS G12D inhibitor RG6620. This study targets patients with MTAP-deleted, KRAS G12D-mutant pancreatic ductal adenocarcinoma. Genentech will sponsor the trial, and both companies will retain commercial rights to their respective compounds.
Read more →IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
IDEAYA Biosciences reported positive results from its OptimUM-02 trial for darovasertib in metastatic uveal melanoma, with plans for a new drug application filing. The company also announced upcoming data presentations at ESMO and a clinical collaboration with Roche for IDE892 in pancreatic cancer. Despite a strong cash position of $1.24 billion, the company reported an increased net loss for the quarter.
Read more →IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers
IDEAYA Biosciences has initiated the Part 2 monotherapy expansion of IDE892 in its Phase 1/2 trial for MTAP-deleted pancreatic and lung cancers. The drug exhibits a promising profile with selective binding properties and has achieved target exposures. The ongoing dose escalation has not yet reached the maximum tolerated dose, indicating further potential for efficacy.
Read more →IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs
IDEAYA Biosciences announced three abstract presentations at the 2026 ESMO meeting, highlighting updates from its clinical pipeline. The presentations will cover ongoing trials of darovasertib in uveal melanoma and IDE849 in small cell lung carcinoma. The company aims to demonstrate the potential of these therapies as new treatment options.
Read more →IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors
IDEAYA Biosciences has elected Yujiro S. Hata as Chairman of the Board. Hata, who is also the President and CEO, has been instrumental in the company's evolution into a leading precision medicine oncology firm. The company is focused on developing breakthrough therapies for cancer, addressing significant unmet medical needs.
Read more →